| __timestamp | CymaBay Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 19586000 |
| Thursday, January 1, 2015 | 17026000 | 29135000 |
| Friday, January 1, 2016 | 15941000 | 42791000 |
| Sunday, January 1, 2017 | 18938000 | 49577000 |
| Monday, January 1, 2018 | 58124000 | 89209000 |
| Tuesday, January 1, 2019 | 83837000 | 69099000 |
| Wednesday, January 1, 2020 | 35882000 | 75961000 |
| Friday, January 1, 2021 | 64542000 | 90467000 |
| Saturday, January 1, 2022 | 67995000 | 74552000 |
| Sunday, January 1, 2023 | 80118000 | 91593000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CymaBay Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
From 2014 to 2023, CymaBay Therapeutics increased its R&D expenses by over 400%, peaking in 2023 with a 51% rise from the previous year. Meanwhile, Supernus Pharmaceuticals consistently outspent CymaBay, with a notable 366% increase in R&D expenses over the same period. In 2023, Supernus's R&D spending reached its highest, marking a 22% increase from 2022.
These trends underscore the strategic focus of both companies on developing new therapies and maintaining a competitive edge in the biopharmaceutical industry.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Supernus Pharmaceuticals, Inc.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Sanofi and CymaBay Therapeutics, Inc.
R&D Insights: How Sanofi and Supernus Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Gilead Sciences, Inc. vs Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Biogen Inc. and Supernus Pharmaceuticals, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
Veracyte, Inc. or Supernus Pharmaceuticals, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Supernus Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.